Wednesday 5th April 2023 |
Text too small? |
Calocurb operates in the natural supplement part of the Life Sciences and Medical Technology sector. It specialises in appetite management, using a unique active ingredient sourced from New Zealand hops believed to be the only natural, non-prescriptive alternative to highly expensive prescription drugs to assist people with chronic and debilitating obesity. Calocurb was formed in 2017, and is classified as early stage, with its technology origins being from Plant and Food Research.
BIF will make a cash investment of $250,000. Following this transaction (and issue of additional units to fund the purchase), Calocurb will represent 1.7% of BIF’s investment portfolio of 32 companies, and with a net asset value of over $14.5 million.
Investors can continue to purchase units in BIF on the NZX or can subscribe for units in the fund as part of the process described in the fund’s Product Disclosure Statement (PDS) that is available at www.booster.co.nz
For further information regarding BIF visit https://www.booster.co.nz/booster-investments/booster-innovation-fund.aspx
For more information, please contact:
Gary Scott
Company Secretary
Booster Investment Management Limited
04 8944300
About Booster
Booster Investment Management Limited (Booster) is the manager and issuer of the Fund, and part of the Booster Group which has been helping New Zealanders save since 1998. The group currently administers superannuation and investment funds of over $5 billion on behalf of more than 170,000 New Zealanders.
BIF is a managed investment fund that invests in early-stage companies founded on intellectual property originated or developed in New Zealand.
For more information, including a copy of the Product Disclosure Statement, please visit www.booster.co.nz
BIF acquires shares in Calocurb
No comments yet
December 31st Morning Report
December 30th Morning Report
December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report